stockportfolio.pro
Charles River Laboratories International, Inc. (CRL)
Healthcare · Diagnostics & Research · NYSE
Charles River Laboratories International, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.68B | $1.86B | $2.27B | $2.62B | $2.92B | $3.54B | $3.98B | $4.13B | $4.05B | $4.02B |
| Gross profit | $1.40B | $1.57B | — | — | — | — | — | — | — | — |
| Net income | $154.76M | $123.36M | $226.37M | $252.02M | $364.30M | $390.98M | $486.23M | $474.62M | $10.30M | $-144.34M |
| Net margin | 9.2% | 6.6% | 10.0% | 9.6% | 12.5% | 11.0% | 12.2% | 11.5% | 0.3% | -3.6% |
Source: Charles River Laboratories International, Inc. SEC filings (10-K). 18 years of history available in the interactive view.
What growth is priced into CRL stock?
At today's market cap of $9.14B, Charles River Laboratories International, Inc. is priced for free-cash-flow growth of about 6% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $518.49M from the FY ending 2025-12-31). For comparison, free cash flow actually grew 6.4%/yr over the last five fiscal years and revenue 6.5%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 18 years of Charles River Laboratories International, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track CRL in your portfolio →
Charles River Laboratories International, Inc. financial history by metric
About Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Charles River Laboratories International, Inc. — frequently asked questions
What is Charles River Laboratories International, Inc.'s revenue?
Charles River Laboratories International, Inc. (CRL) reported revenue of $4.02B for fiscal year 2025, down 0.9% from the prior year, according to its SEC filings.
Is Charles River Laboratories International, Inc. profitable?
No — CRL reported a net loss of $-144.34M in fiscal 2025.
What is CRL's P/E ratio?
Charles River Laboratories International, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Charles River Laboratories International, Inc. growing?
CRL's revenue grew at roughly 6.5% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Charles River Laboratories International, Inc. have?
As of fiscal year 2025, CRL carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Charles River Laboratories International, Inc.'s market cap?
Charles River Laboratories International, Inc. (CRL) has a market capitalization of about $9.14B, based on the latest data in our nightly-refreshed cache.
When does Charles River Laboratories International, Inc.'s fiscal year end?
CRL's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into CRL stock?
At today's market cap of $9.14B, Charles River Laboratories International, Inc. is priced for free-cash-flow growth of about 6% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $518.49M from the FY ending 2025-12-31). For comparison, free cash flow actually grew 6.4%/yr over the last five fiscal years and revenue 6.5%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Charles River Laboratories International, Inc.'s official SEC filings (10-K and 10-Q), covering 18 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.